Xencor logo

Xencor

XNCR | NASDAQ
Chart Builder DCF Calculator
$35.40
-$1.69 (-4.56%)
At close: Nov 16, 2026, 4:00 PM ET
$35.40
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.56%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
55.7
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #176/1021 (Top 17%)

Key Statistics

Market Data

Market Cap $2.66B
1D Range
35.34 37.38
52W Range
10.41 39.97

Valuation (TTM)

PE -22.26
PB 4.74
EV/EBITDA -29.33

Valuation (NTM)

Forward PE N/A
Forward PEG -0.62
Price Target $44.00
Loading financial charts...

Profile

Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated ...

Sector Healthcare
Industry Biotechnology
Employees 260
IPO Date Dec 3, 2013
Fiscal Year January - December

Latest News

Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657

8 days ago · businesswire.com

Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657
Xencor (XNCR) Q3 Earnings and Revenues Beat Estimates

12 days ago · zacks.com

Xencor (XNCR) Q3 Earnings and Revenues Beat Estimates
Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway

21 days ago · seekingalpha.com

Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer

21 days ago · marketbeat.com

Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript

22 days ago · seekingalpha.com

Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript
Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

22 days ago · benzinga.com

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and

23 days ago · gurufocus.com

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

23 days ago · businesswire.com

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

29 days ago · businesswire.com

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor to Present at the 2026 Cantor Global Healthcare Conference

3 months ago · businesswire.com

Xencor to Present at the 2026 Cantor Global Healthcare Conference

Earnings

Latest Earnings
Nov 4, 2026
EPS
$0.5
Beat +249.64%
REV
$116.52M
Beat +84.96%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$44.00
Upside
+24.29%
Buy (7)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.